Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

DataM Intelligence | competitive Intelligence NF1 drug development accelerates with novel treatments aiming to surpass current MEK inhibito ...

With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug ...

Merck MRK announced encouraging data from the dose confirmation portion of the phase II/III waveLINE-003 study evaluating its ...